

WHETSTINE LABORATORY

CANCER CENTER Addressing the Problem of Drug-Resistant Cancer



Current Funding Sources:

National Institute of Health

American Lung Association


American Cancer Society

Leukemia & Lymphoma Society

Alex's Lemonade Stand Foundation


Johnathan Whetstine, PhD

Cancer cells that stop responding to therapy (referred to as drug-resistant cancer) result in patients losing their lives. Understanding how to prevent and/ or treat resistance will influence the next generation of cancer therapies and save lives. In studying how cancer cells become drug-resistant, Johnathan Whetstine, PhD, and his team in the Whetstine Laboratory at the Mass General Center for Cancer Research recently uncovered a protein that generates specific DNA fragments containing genes that cause cancer cells to become resistant to chemotherapy. This allows replicating cancer cells to grow and defend themselves against previously effective treatments (Figure 1).



@WhetstineLab
"TacklingCancer For
A Better Tomorrow"

Published Cover Images





The Whetstine Laboratory's discovery was the first of its kind, and provides a new way to understand how cancer cells change their DNA content and potentially acquire the ability to become treatment resistant (Figure 1). In fact, their discovery identified a new protein to evaluate in tumors and directly relates to cancer cell response to therapy. Most recently, Dr. Whetstine's group used a drug to target the protein and was able to block the extra DNA pieces associated with drug resistance. These findings illustrate the importance of evaluating this protein in tumors and demonstrate that this process does not occur randomly but can be directed and targeted by proteins within the cell. Dr. Whetstine's group is currently uncovering additional genes and conditions that can generate extra DNA pieces involved in cancer cell drug resistance.





Figure 1. The impact of DNA copy gains and goals related to Dr. Whetstine's projects.

This work holds promise for the development of new strategies to block resistance to chemotherapies and targeted therapies with broad and profound implications for many different types of cancer.

Cancers types our research program is targeting:

Lung Cancer Myeloma Breast Cancer Ovarian Cancer Neuroblastoma

Published Cover Image



Contact Information:

jwhetstine@hms.harvard.edu

Twitter:

@WhetstineLab

Facebook: Whetstine Lab

Website:

www.whetstinelab.com